期刊
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
卷 40, 期 22, 页码 12358-12379出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/07391102.2021.1970627
关键词
Terminalia arjuna; catalase inhibition; SARS-CoV-2 protease; arjunetin; molecular docking; molecular dynamic simulations
资金
- DST [CRG/2018/000430, DST/SJF/CSA-03/2018-10, SB/SJF/2019-20/12]
- SERB [CRG/2018/000430, DST/SJF/CSA-03/2018-10, SB/SJF/2019-20/12]
- IIT Madras
The ethanolic bark extract of Terminalia arjuna tree contains bio-active compound arjunetin, which exhibits inhibition of catalase activity and potential antiviral activity, particularly against SARS-CoV-2. Molecular docking and dynamics studies show that arjunetin has higher binding affinity than Remdesivir in targeting key proteins of the virus. These findings suggest that arjunetin could be a promising drug candidate against Covid-19.
Stem and bark of the tree Terminalia arjuna Wight & Arn. (Combretaceae) has been documented to exhibit therapeutic properties like cardiotonic, anticancer, antiviral, antibacterial, antifungal, hypercholesterolemia, hypolipidemic, and anti-coagulant. Our previous studies have shown that, ethanolic extract of T. arjuna bark exhibits radical scavenging anti-oxidant activity and also effectively inhibited catalase activity. In this study, oleanane triterpenoids type compounds viz., oleanolic acid, arjunolic acid, arjunolitin, arjunetin were isolated from ethanolic bark extract as bio-active compound and their structures were elucidated using H-1, C-13 NMR, HR-ESIMS, IR. Of the various compounds, Arjunetin showed significant inhibition of catalase activity as compared to the other compounds. Based on the structural similarity between arjunetin and current antiviral drugs, we propose that arjunetin might exhibit antiviral activity. Molecular docking and molecular dynamics studies showed that arjunetin binds to the binds to key targets of SARS-CoV-2 namely, 3CLpro, PLpro, and RdRp) with a higher binding energy values (3CLpro, -8.4 kcal/ mol; PLpro, -7.6 kcal/mol and RdRp, -8.1 kcal/mol) as compared with FDA approved protease inhibitor drugs to Lopinavir (3CLpro, 7.2 kcal/mole and PLpro 7.7 kcal/mole) and Remdesivir (RdRp 7.6 kcal/ mole). To further investigate this, we performed 200-500 ns molecular dynamics simulation studies. The results transpired that the binding affinity of Arjunetin is higher than Remdesivir in the RNA binding cavity of RdRp. Based on structural similarity between arjunetin and Saikosaponin (a known antiviral agents) and based on our molecular docking and molecular dynamic simulation studies, we propose that arjunetin can be a promising drug candidate against Covid-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据